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A B S T R A C T
Objective: In a budget-constrained health care system, decisions regarding resource alloca-
tion towards research and implementation are critical and can be informed by cost-effective-
ness analysis. The objective of this studywas to assess the societal value of conducting further
research to informreimbursementdecisions and implementationof cost-effective psychother-
apy for clusters B and C personality disorders (PDs).
Methods: Value of information and value of implementation analyses were conducted
using previously developed cost-effectiveness models for clusters B and C PDs to evaluate
the parameters that contribute to most of the decision uncertainty, and to calculate the
population expected values of perfect information (pEVPI) and perfect implementation
(pEVPIM).
Results: The pEVPI was estimated to be €425 million for cluster B PDs and €315 million for
cluster C PDs, indicating that gathering additional evidence is expected to be cost-effective.
The categories of parameters for which reduction of uncertainty would be most valuable
were transition probabilities and health state costs. The pEVPIM was estimated to be €595
million for cluster B PDs and €1,372 million for cluster C PDs, suggesting that investing in
implementation of cost-effective psychotherapy is likely to be worthwhile.
Conclusions: The societal value of additional research on psychotherapy for clusters B and
C PDs is substantial, especiallywhen prioritizing information on transition probabilities and
health state costs. Active implementation of cost-effective treatment strategies into clinical
practice is likely to improve the efficiency of health care provision in The Netherlands.
Copyright © 2011, International Society for Pharmacoeconomics and Outcomes Research
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Cost-effectiveness analyses increasingly are being used to in-
form policy decisions regarding the adoption and reimburse-
ment ofmental health interventions. Recently, two decision-an-
alytic modeling studies evaluated the cost-effectiveness of
variousmodalitiesofpsychotherapy in treatingclusterBperson-
ality disorders (PDs) [1], including borderline, antisocial, histri-
onic, and narcissistic PDs, and cluster C PDs [2], including
avoidant, dependent, and obsessive-compulsive PDs. Results
indicate that, at a societalwillingness to pay of €40,000 per quality-
djusted life year (QALY), outpatient psychotherapy is the optimal
reatment for patients with cluster B PDs, whereas short-term in-
atientpsychotherapy is themostcost-effectivechoice forpatients
ith cluster C PDs. If the objective of the health care system is to
aximize gains in health outcome subject to a budget constraint,
hesetreatmentstrategiesare,onaverage,expectedtogeneratethe
ighest level of net benefit and should be adopted.
The decision of whether to adopt a treatment strategy is
navoidably subject to uncertainty, as current information on
osts and effects is rarely perfect or complete. If the decision
ased on existing information turns out to bewrong, therewill
e costs in terms of health benefit and resources forgone, be-
ause patients are assigned to suboptimal treatment strate-
ies. An important question, therefore, is whethermore infor-
ation regarding these decisions is desirable [3]. Gathering
dditional evidence for uncertain parameters is valuable be-
ause it is expected to reduce decision uncertainty and, thus,
he probability and the net consequences of a wrong decision;
owever, it is not without costs.
Although our evidence-based findings of cost-effective
are in treating personality disorders can inform recommen-
ations for clinical guidelines, it does not guarantee diffusion
nto clinical practice. This imperfect translation into clinical
outines may be due to limited availability in settings where
atient demand exceeds treatment capacity. Moreover, it is
nlikely that clinicians will immediately alter their profes-
ional practice once a treatment is identified as cost-effective
4]. Adherence to suboptimal treatment strategies will com-
romise the efficiency of health care provision, resulting in
ealth and resources forgone [5]. Resources need to be allo-
ated toward active implementation of cost-effective treat-
ent strategies using activities such as restructuring and
lanning of care or education and training of professionals.
Cost-effective health care policy involvesmaking decisions
bout the reimbursement of cost-effective treatments as well
s weighing the potential value of collecting additional evi-
ence and implementation efforts against the costs of these
ctivities. Adequate priority setting and efficient resource al-
ocation thus requires an integral economic analysis of these
eparate but related options to improve care.
This study places an upper bound on the value of conducting
urther research regarding the decision question of cost-effec-
ive psychotherapy for clusters B and C PDs and aims to feed the
riority-setting process by indicating which type of research
ould bemost valuable. Additionally, the potential worth of en-
uring the implementation of cost-effective care for these pa-
ient populations is estimated. We use a single, unified frame-ork that evaluates the uncertainty associated with the
doptiondecisions toestimateboth thevalueof informationand
he value of implementation [6,7]. The findings from our study
can be used to informpolicy debates regarding the efficient allo-
cation of health care resources among health care provision, re-
search funding, and investments in implementation strategies.
Methods
Patient population and empirical data
Based on the prevalence of cluster C PDs (median 4.2%; 1.4%
avoidant PDs, 0.8% dependent PDs, and 2.0% obsessive-com-
pulsive PDs) [8] in the population of The Netherlands
(16,377,153), the percentage of treatment-seeking patients
with a PD (19.1%) [9], and the percentage of patients with a PD
receiving psychotherapy (16.4%), we estimated the annual in-
cident cluster C PD population eligible for treatment to be
21,546 patients. The total eligible population (discounted over
5 years) was calculated to be 99,756. The various modalities of
psychotherapy in treating patients with cluster C PDs include
long-term outpatient psychotherapy, short-term and long-
term day hospital psychotherapy, and short-term and long-
term inpatient psychotherapy.
For cluster B PDs (median 6.0%; 1.5% borderline PDs, 2.6%
antisocial PDs, 1.8%histrionic PDs , and 0.1%narcissistic PDs) [8],
we assumed the incidence of eligible patients per annum to be
30,780 and the total eligible population (discounted over 5 years)
to be 142,508. Treatment options include outpatient psychother-
apy, day hospital psychotherapy, and inpatient psychotherapy.
Patient-level data were obtained from the largest existing
clinical trial of psychotherapy for PDs (the SCEPTRE trial),
which included over 900 patients [1,2]. Patients were assigned
to one of the treatment groups, based on a comprehensive
assessment battery combined with the expert opinion of cli-
nicians. To avoid selection bias, we controlled for initial dif-
ferences in patient characteristics with the multiple propen-
sity score method [10].
With 63 out of 448 cluster C patients of the SCEPTRE popu-
lation receiving short-term inpatient psychotherapy, we as-
sumed the current level of implementation to be 0.141. For
long-term outpatient psychotherapy, short-term day hospital
psychotherapy, long-term day hospital psychotherapy, and
long-term inpatient psychotherapy, we estimated the current
level of implementation to be 0.214, 0.190, 0.230, and 0.225, re-
spectively. For cluster B PDs, 57 out of 241 patients received out-
patient psychotherapy; therefore, we assumed the current level
of implementation to be 0.237. For day hospital psychotherapy
and inpatient psychotherapy the current level of implementa-
tion was estimated to be 0.411 and 0.353, respectively.
Cost-effectiveness analysis and decision uncertainty
Cost-effectiveness analyses were previously conducted using a
Markov cohortmodel based on second-orderMonte Carlo simu-
lation [11]. Results were reported from the societal perspective
and in terms of costs per QALY gained. To be consistent with
most other cost-effectiveness studies that are based on clinical
.231V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 2 9 – 2 3 9trials in the literature, we selected a five-year time horizon,
which is two years beyond the duration of the clinical trial.
The model simulates a cohort of patients that transition
through five mutually exclusive health states that represent
important attributes of disease. These health states include:
1) recovered; 2) improved; 3) unchanged; 4) relapsed or deteri-
orated; and 5) death. Themodel is used to assess the impact of
different modalities of psychotherapy on the costs and health
outcomes of the patient population over time.
Model parameters were obtained from the SCEPTRE trial.
Each parameter was assigned a distribution of values in order to
characterize the uncertainty in the data (e.g., gamma distribu-
tions for costs, betadistributions for utilities).Weassumedprob-
abilityparameters followedaDirichletdistribution,acontinuous
distribution that is the multivariate generalization of the beta
distribution. Details of model design and analyses have been
described in previous publications [1,2].
In order to explore parameter uncertainty of the model in-
puts, probabilistic sensitivity analysis was conducted by ran-
domly sampling from each of the parameter distributions. The
expected costs, and expectedQALYs for each treatment strategy
were calculated using that combination of parameter values in
themodel. This process was replicated one thousand times (i.e.,
second-orderMonteCarlo simulation) for each treatment option
resulting in the expected cost-effectiveness. Decision uncer-
tainty is represented in the cost-effectiveness acceptability fron-
tiers (CEAF) [12], which plot the probability that the treatment
strategywith themaximumexpected netmonetary benefit is in
fact the most cost-effective over a range of willingness-to-pay
threshold values. As reported previously, we found that outpa-
tient psychotherapy was the most cost-effective treatment for
cluster BPDsandshort-term inpatient psychotherapy for cluster
C PDs at a threshold of €40,000 per QALY (Table 1).
Value of information and value of implementation analysis
To explore both the value of information and the value of
Table 1 – Cost-effectiveness results over five years [1,2].
Psychotherapy dosage
Cost
Short-term day hospital €89,411
Long-term outpatient €89,936
Short-term inpatient €91,620
Long-term day hospital €105,940
Long-term inpatient €119,946
Modality of psychotherapy
Cost
Outpatient €80,247
Day hospital €91,090
Inpatient €97,351
* Incremental cost-effectiveness ratios (ICER) were calculated as the dif
the next best non-dominated strategy. The optionwith the highest IC
† Net monetary benefit (NMB) was calculated by multiplying QALY
strategy with the maximum NMB is the most cost-effective choiceimplementation we used a framework matrix developed byFenwick and colleagues [6] representing a four-state world
where both information and implementation can be either at
the current level or perfect (Table 2). By subtracting the ex-
pected values for different states, the maximum societal val-
ues associated with further research and implementation ef-
forts can be calculated. These upper bound estimates should
be weighed against the costs of these activities to determine
whether they are worthwhile.
Expected value of perfect information
Compared to informationat thecurrent level about thecostsand
effects of the different treatment strategies for PDs, perfect in-
formation would eliminate the possibility of making the wrong
reimbursement decision. The expected values of perfect infor-
mation (EVPI) can be interpreted as the maximum that the
health care system would be willing to pay for additional evi-
dence to inform the reimbursement decision in the future, and it
places an upper bound on the value of conducting further re-
search.
For both cluster B and cluster C cost-effectiveness analyses,
the EVPI was calculated, illustrated in Table 3 for a cluster C
patient. The table represents output from6of the total 1000 sim-
ulations generating net monetary benefits for each of the treat-
ment strategies.With current information, short-term inpatient
psychotherapy is the optimal decision because this intervention
generates the highest expected net benefit (€51,124, at a thresh-
old of €40,000 per QALY). With perfect information the decision
Cluster C PD
QALY ICER* NMB†
3.44 — €48,001
3.30 Dominated €42,135
3.57 €16,570 €51,124
3.49 Dominated €33,670
3.49 Dominated €19,731
Cluster B PD
QALY ICER* NMB†
3.11 — €44,072
3.30 €56,325 €40,929
3.32 €286,493 €35,542
ce in cost divided by the difference in QALYs between the strategy and
low the threshold of €40,000 per QALY is themost cost-effective choice.
the threshold value of €40,000 per QALY and subtracting cost. The
Table 2 – Framework matrix for determining the
expected value of perfect information and of perfect
implementation [6].
Information
Current Perfect
Implementation
Current A Bferen
ER be
s byPerfect C D
r
t
2
i
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efit for each simulation; that is, choose long-term outpatient
psychotherapy for simulation 1. short-term inpatient psycho-
therapy for simulation 2, short-term day hospital for simulation
3, and so on. The benefits forgone are the difference in the net
monetary benefits between the optimal strategy for a given sim-
ulation and the strategy identified as optimal in the adoption
decision (i.e., short-term inpatient psychotherapy). The expecta-
tion of benefits forgone over all simulations represents the EVPI
per individual (€3,159, at a threshold of €40,000 per QALY). This
esult can also be calculated by taking the difference between
he expectednet benefitwithperfect information (cell D inTable
) and the expected net benefit with current information (cell C
n Table 2).
Expected value of partial perfect information
The expected value of partial perfect information (EVPPI) iden-
tifies the input parameters in the decisionmodel that contrib-
ute to most of the decision uncertainty and for which future
research is most valuable.
The model parameters were grouped into four subsets to
match the type of research that would be conducted: 1) transi-
tionprobabilitiesbetweenhealth states; 2) treatment costsof the
different modalities of psychotherapy; 3) health state costs,
which reflect the costs of health careutilizationandproductivity
losses incurred by patients in each state; and 4) health state util-
ities, which reflect the health-related quality of life experienced
by patients in each state. The EVPPI for the parameter groups
was calculated with a similar approach as for EVPI by taking the
difference between the expected value of a decision made with
perfect and current information about the parameters.
Expected value of perfect implementation
The current, imperfect implementation of cost-effective treat-
ment strategies into clinical practice compromises the expected
efficiencyofpatientmanagement in termsofhealthbenefitsand
resources forgone. As such, there is value in actively ensuring
Table 3 – Calculating expected value of perfect information
Simulation Net mo
Long-term
outpatient
Short-term
day
hospital
L
Expectation €42,135 €48,001
1 €55,335 €49,862
2 €38,142 €42,243
3 €49,584 €53,749
4 €55,344 €51,292
5 €41,341 €55,000
. . . . . . . . .
1000 €48,833 €47,462
Decision based on current information: Short-term inpatient psycho
Decision based on perfect information: underlined.
Expected net benefit with current information: €51,124.
Expected net benefit with perfect information: €54,283.
Expected value of perfect information: €54,283  €51,124  €3,159.
* Net monetary benefit was calculated by multiplying effect by societ
ratio of €40,000 per QALY.the implementation of cost-effective clinical guidelines. The ex-pected value of perfect implementation (EVPIM) provides amea-
sureof theupperboundof thevalueof implementationefforts to
change capacity of and adherence to cost-effective treatment
strategies. For both cluster B and cluster C cost-effectiveness
analyses, the EVPIM was calculated by taking the difference be-
tween the expected net benefit with perfect implementation
(cell C in Table 2) and the expected net benefit with implemen-
tationat its current level (cellA inTable2).Netmonetarybenefits
for the expected valuewith current implementationwere calcu-
lated by taking theweighted average of the expected net benefit
with perfect implementation (and current information), where
the weights reflect the current level of implementation.
Expected value of perfection
The expected value of perfection (EVP) is a combinedmeasure of
the maximum possible return to resources expended on re-
search and implementation strategies. The EVP was calculated
by taking the difference between the expected net benefit with
both perfect information and implementation (cell D in Table 2)
and the expected net benefitwith information and implementa-
tion at its current level (cell A in Table 2).
We assumed the expected lifetime of psychotherapy (i.e., the
time horizon over which additional researchwould be useful) to
befive years, but explored the influenceof a longer timehorizon.
Because information and implementation are expected to
serve the public domain, the EVPI, EVPPI, EVPIM, and EVP were
calculated at the population level by multiplying the patient-
level values by the number of patients who will receive psycho-
therapy over the assumed time horizon for the intervention.
Caseswere discounted at an annual rate of 4.0%, consistentwith
guidelines for economic evaluations in The Netherlands [13].
Base case and sensitivity analysis
In the base case analyses, a societal willingness-to-pay
threshold value of €40,000 per QALY was used. The expected
PI) for an individual cluster C patient.
ry benefits* Maximum
net
benefit
Benefits
forgone
term
y
ital
Short-term
inpatient
Long-term
inpatient
,670 €51,124 €19,731 €54,283 €3,159
,609 €53,739 €47,329 €55,335 €1,595
,939 €52,331 €32,884 €52,331 €0
,813 €49,132 €48,165 €53,749 €4,617
,785 €62,637 €48,807 €62,637 €0
,338 €48,924 €7,029 €55,000 €6,075
. . . . . . . . . . . . . .
,071 €68,596 €7,354 €68,596 €0
py.
llingness to pay and subtracting cost, with willingness to pay set at a(EV
neta
ong-
da
hosp
€33
€30
€29
€26
€46
€36
.
€34
thera
al wilifetime of psychotherapy was assumed to be five years.
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233V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 2 9 – 2 3 9In sensitivity analyses, the decision uncertainty and popula-
tion EVPI, EVPIM, and EVPwere calculated for different values of
thewillingness-to-pay threshold. In addition,we studied the im-
pact of the current level of implementation, the time horizon of
analysis, and the size of the eligible patient population on the
expectedpopulationvalues of informationand implementation.
In all analyses, the expected population values were calcu-
lated across 1,000 Monte Carlo simulations with 1,000 draws
from the parameter group of interest.
Results
Base case analysis
Table 1 summarizes the currently available evidence on the
costs andeffects of thefivealternative treatmentdosagesof psy-
chotherapy for cluster C PDs and three psychotherapy modali-
ties for cluster B PDs, and denotes themost cost-effective choice
(i.e., the option with the highest incremental cost-effectiveness
ratio [ICER] below the threshold, or the option that maximizes
net monetary benefit) at a willingness-to-pay threshold of
€40,000 per QALY. With current information, short-term inpa-
tient psychotherapy for cluster C PDs is the optimal decision as
this intervention generates the highest expected net benefit
(€51,124, at a threshold of €40,000perQALY). Theprobability that
hort-term inpatient psychotherapy is indeed cost-effective is
nly 0.52; therefore, there is value in reducing the error probabil-
Table 4 – Framework matrix for different dosages of psych
For individual patients (€)
Implementation
Current
Perfect
For the total eligible population (€ millions)
Implementation
Current
Perfect
EVP, expected value of perfection; EVPI, expected value of perfect inf
the population; pEVPI, EVPI of the population; pEVPIM, EVPIM of the
* Given the simplifying assumption that the level of implementatio
decision made on the basis of perfect information (cell B) was equi
information (cell A).ty of 0.48 by collecting additional evidence. Assuming imple- tentation is perfect, the EVPI for individual patients is €3,159
ver a five-year time horizon; with 99,756 eligible patients in the
opulation, the pEVPI is €315million (Table 4). Based on the cur-
ent level of information, the EVPIM for individual patients is
13,754 over a five-year time horizon; with 99,756 eligible pa-
ients in the population, the pEVPIM) is €1,372 million.
Likewise, outpatient psychotherapy provides the highest
xpected net benefit for cluster B PDs (€44,072, at a threshold
f €40,000 per QALY). The probability that outpatient psycho-
herapy is cost-effective is 0.51; in that case, the EVPI for indi-
idual patients is €2,984 over a five-year time horizon and the
EVPI is €425 million (Table 5).
Based on the current level of information, the EVPIM for
ndividual patients is €4179 over a five-year time horizon and
595 million for the eligible population (pEVPIM).
The population expected value of perfection (pEVP) was
1,687 million for cluster C PDs (€16,913 for individual pa-
ients) (Table 4) and €1,021 million for cluster B PDs (€7,163
or individual patients) (Table 5), suggesting that there is
onsiderable scope for improving the efficiency of health
are provision for cluster B and cluster C patients with PDs.
Figure 1A displays the pEVPPI for the four groups of param-
ters at a cost-effectiveness threshold of €40,000 perQALY and
five-year lifetime for psychotherapy. The pEVPPI associated
ith transition probabilities and health state costs are rela-
ively high; research that would eliminate the uncertainty in
hese subsets of parameters would be worth €232 million and
39 million, respectively (€2328 and €390 for individual pa-
rapy in treating cluster C personality disorders.
Information
Current Perfect
37,370 (A) 37,370 (B)*
51,124 (C) 54,283 (D)
Information
Current Perfect
3,728 (E) 3,728 (F)*
5,100 (G) 5,415 (H)
Societal willingness to pay per QALY €40,000
Total eligible population over 5 years 99,756
EVPI for patient  D  C  €3,159
pEVPI (in million)  H  G  €315
EVPIM for patient  C  A  €13,754
pEVPIM (in million)  G  E  €1,372
EVP for patient  D  A  €16,913
pEVP (in million)  H  E  €1,687
tion; EVPIM, expected value of perfect implementation; pEVP, EVP of
lation.
ot influenced by the level of information, the expected value of the
t to the expected value of the decision made on the basis of currentothe
orma
popu
n is n
valenients). In contrast, the model input parameters related to
tted va
234 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 2 9 – 2 3 9treatment costs have lower value of information (€1.4 million
or €14 for individual patients), and health state utilities have
hardly any value of information (€162,759 or €2 for individual
patients). Note the pEVPPI for the groups of parameters do not
Table 5 – Framework matrix for different modalities of psy
For individual patients (€)
Implementation
Current
Perfect
For the total eligible population (€ millions)
Implementation
Current
Perfect
EVP, expected value of perfection; EVPI, expected value of perfect inf
the population; pEVPI, EVPI of the population; pEVPIM, EVPIM of the
* Given the simplifying assumption that the level of implementation is not
on the basis of perfect information (cell B) was equivalent to the expec
Fig. 1 – Population expected value of partial perfect information
(pEVPPI) at a cost-effectiveness threshold of €40,000 per QALY
and assuming a 5-year lifetime for psychotherapy. A, pEVPPI for
cluster C PDs. B, pEVPPI for cluster B PDs.sum to the overall pEVPI for the model, attributable to the
interactions within the model structure.
Figure 1B shows that the pattern of partial EVPI for clus-
ter B PDs is very similar to that of cluster C PDs, with rela-
tively high values associated with transition probabilities
and health state costs (pEVPPI of €193 million and €160 mil-
lion, respectively; €1351 and €1123 for individual patients).
The value of information associated with treatment costs is
much lower (€1.4 million; €10 for individual patients), and
he value associated with health state utilities is zero.
Sensitivity analysis
Level of the societal willingness to pay per QALY
Figure 2A illustrates the relationship between the CEAF, pEVPI,
pEVPIM, and pEVP and the societal willingness to pay per QALY
for the adoption decision regarding the five plausible treatment
strategies for cluster C PDs. The extent of uncertainty sur-
rounding the decision is formally quantified in the pEVPI
curve. This curve initially increases as the cost-effective-
ness threshold rises, with a local maximum occurring at the
value corresponding to the ICER of €16,570 per QALY; at this
point the optimal option changed from short-term day hospi-
tal psychotherapy to short-term inpatient psychotherapy, and
the choice between strategies ismost uncertain (illustrated by
the relatively low CEAF values). The pEVPI curve decreases
when the threshold is higher than the ICER, suggesting that
the falling probability of error of the decision to adopt short-
herapy in treating cluster B personality disorders.
Information
Current Perfect
39,893 (A) 39,893 (B)*
44,072 (C) 47,056 (D)
Information
Current Perfect
5,686 (E) 5,686 (F)*
6,281 (G) 6,706 (H)
Societal willingness to pay per QALY €40,000
Total eligible population over 5 years 142,508
EVPI for patient  D  C  €2,984
pEVPI (in million)  H  G  €425
EVPIM for patient  C  A  €4,179
pEVPIM (in million)  G  E  €595
EVP for patient  D  A  €7,163
pEVP (in million)  H  E  €1,021
tion; EVPIM, expected value of perfect implementation; pEVP, EVP of
lation.
encedby the level of information, the expectedvalueof thedecisionmade
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235V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 2 9 – 2 3 9the value of the consequences of error, which are valuedmore
highly at higher thresholds.
Indicating the maximum return to investments in imple-
mentation, the pEVPIM curve initially decreases as the cost-
effectiveness threshold rises with a local minimum occurring
at the value that corresponds to the ICER. At this point deci-
sion makers are indifferent about which of the cost-effective
strategies are implemented. The value is, however, not zero,
because there is value to be gained from reducing the current
adherence to suboptimal treatment options (e.g., long-term day
hospital psychotherapy and long-term inpatient psychother-
apy). ThepEVPIMcurve rises for threshold values above the ICER
as a result of the increasing value to be gained from implement-
ing short-term inpatient psychotherapy, which is identified
(with increasing certainty) as the optimal treatment strategy.
The pEVP curve can be derived by summing pEVPI and
pEVPIM and displays a gradual increase over the full range
of threshold values.
Figure 2B shows the CEAF, pEVPI, pEVPIM, and pEVP as a
function of the cost-effectiveness threshold for the adoption de-
cision regarding the three possible treatment strategies for clus-
ter B PDs. Initially, the pEVPI values are relatively low and the
Fig. 2 – Population expected values of perfect information (p
(primary axis) and cost-effectiveness acceptability frontier (C
to pay (WTP) for the adoption decision regarding( A) the five
treatment strategies for cluster B PDs.pEVPIM values relatively high, indicating that there is not muchuncertainty surrounding the adoption of outpatient psychother-
apy reflected byhigh values associatedwith strategies to change
implementation. The steep pEVPIM curve reaches a minimum
and the pEVPI curve amaximumwhen the threshold equals the
ICER of €56,325 per QALYwhere there is a change in the optimal
reatment strategy fromoutpatient psychotherapy to dayhospi-
al psychotherapy. At this point the probability of making a
rongdecision is relatively high (illustrated by the relatively low
EAF values) and policymakers are indifferentwhich treatment
o implement. In contrast to the pEVPI for the cluster C analysis,
he curve gradually increases when the threshold is higher than
he ICER, suggesting that the rise in the value of the conse-
uences of error outweighs the gradually falling probability of
rror of the decision to adopt short-term day hospital psycho-
herapy (reflected by the CEAF).
The U-shaped pEVP curve shows that with increasing
hreshold values, there is alternately less, equal, and more
otential value associated with research funding than with
nvestments in implementation.
Level of current implementation
Figure 3 displays the impact of the level of current implemen-
), perfect implementation (pEVPIM), and perfection (pEVP)
) (secondary axis) as a function of the societal willingness
tment strategies for cluster C PDs and (B) the threeEVPI
EAF
treatation on the expected population values of information
m
r
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i
h
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c
236 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 2 9 – 2 3 9(pEVPI), implementation (pEVPIM), and perfection (pEVP). At a
cost-effectiveness threshold of €40,000 per QALY, outpatient
psychotherapy for cluster B PDs and short-term inpatient
psychotherapy for cluster C PDs are the most cost-effective
treatment strategies and the optimal level of implementa-
tion would be 1. When the current level of implementation is 1,
the pEVPIM is 0 because all patients are receiving themost cost-
effective treatment.Whenthecurrent level of implementation is
0, the pEVPIM is €1,597million for cluster C PDs (Fig. 3A) and €780
illion for cluster B PDs(Fig. 3B).With an increasing level of cur-
ent implementation, the pEVPIM curve decreases as more pa-
ients receive the optimal treatment and strategies to change
mplementation have less value. The level of implementation
as no impact on the pEVPI, becausewe assumed perfect imple-
entation. The pEVP curve decreases with increasing level of
urrent implementation.
Selection of time horizon
Varying the time horizon over which the pEVPI, pEVPIM, and
pEVP are calculated influenced the results crucially (Fig. 4).We
found that aswe extended the time horizon beyond five years,
the population expected values increased.
Size of the eligible population
The size of the eligible patient population has a direct impact
Fig. 3 – Population expected values of perfect information (p
as a function of the level of current implementation of the m
A, short-term inpatient psychotherapy for cluster C PDs. B, oon the population-level estimates of the pEVPI, pEVPIM, andpEVP (not shown). With increasing size of the eligible patient
population per annum, the population expected values are
increasing.
Discussion
Extending from previous cost-effectiveness analyses, we esti-
mated the societal value of conducting additional research
related to the adoption decisions of cost-effective psychother-
apy for cluster B and cluster C PDs. To our knowledge, this is
the first formal measure of value of information regarding
mental health interventions. It is important to note that, al-
though health care systems invest heavily in research, re-
search prioritization is generally not based on a unified and
coherent framework. Simultaneously, we used value of imple-
mentation analysis to determine the potential worth of imple-
menting these cost-effective treatment strategies into clinical
practice. Therefore, this study has the potential to contribute
significantly to the knowledge base guiding rational decision
making of allocation of health care resources across health
care provision, research funding, and implementation invest-
ments within and between broad clinical areas.
Our findings indicate that the societal value of additional
research is substantial, estimated at €425 million for cluster B
), perfect implementation (pEVPIM), and perfection (pEVP)
cost-effective treatment at a threshold of €40,000 per QALY.
tient psychotherapy for cluster B PDs.EVPI
ost
utpaPDs and €315 million for cluster C PDs, assuming a willing-
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237V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 2 9 – 2 3 9ness-to-pay threshold of €40,000 per QALY and a five-year life-
time for psychotherapy. The expected value of partial perfect
information associated with themodel parameters (EVPPI) in-
dicate that more evidence about transition probabilities be-
tween health states and health state costs would be most
valuable, whereas additional evidence about treatment costs
and health state utilities would be of relatively little or no
value. Considering the current level of implementation of cost-
ffective psychotherapy in clinical practice and a threshold
alue of €40,000 per QALY, there is substantial societal benefit in
hanging the capacity of and adherence to cost-effective treat-
ent strategies, with the EVPIM estimated to be €595million for
luster B PDs and €1,372 million for cluster C PDs.
The upper bound value of psychotherapy research for PD
alls comfortably within the results of a pilot study summariz-
ng the evidence of six case studies evaluating value of infor-
ation ranging from £2.8 million (liquid based cytology
creening for cervical cancer) and £865 million (clopidogrel
nd dipyridamole in the secondary prevention of occlusive
ascular events) [14].
The EVPI and EVPIM provide the necessary, but not suffi-
ient, conditions for further research and implementation;
hether these activities should be undertaken requires
nowledge of the expected net benefit from a particular re-
earch or implementation project (i.e., the difference between
Fig. 4 – Population expected values of perfect information (p
as a function of the selection of time horizon at a threshold
cluster C PDs. B, outpatient psychotherapy for cluster B PDs.he expected value of sample information and the cost of spe-cific research). It is important to emphasize that only when a
future study has a probability of changing the optimal strategy
will there be benefits in terms of a reduction in the expected
loss from uncertainty. In formulating policy recommenda-
tions andprioritizing research and/or implementation, the ex-
pected net benefit from a particular research or implementa-
tion project regarding psychotherapy for clusters B and C PDs
should be compared with the expected net benefit of other
unrelated proposed clinical research and implementation
projects. From the policy perspective, we recommend reim-
bursement of outpatient psychotherapy for cluster B PDs and
short-term inpatient psychotherapy for cluster C PDs while
simultaneously commissioning further research into the cost-
effectiveness of proposed clinical research and implementa-
tion projects in order to more efficiently allocate health care
resources.
In our expected value of information calculations, we arbi-
trarily selected a time horizon of five years, commonly used in
clinical trial-based cost-effectiveness analyses. Although it
has been suggested that the analytic time horizon should ide-
ally encompass future changes in technologies, prices, and
evidence, there are currently no well-established methods in
choosing the appropriate time horizon [15].
The pEVPI, pEVPIM, and pEVP are heavily influenced by the
level of current implementation, the size of the eligible patient
), perfect implementation (pEVPIM), and perfection (pEVP)
0,000 per QALY. A, short-term inpatient psychotherapy forEVPI
of €4population, the selected time horizon, and the societal will-
238 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 2 9 – 2 3 9ingness to pay per QALY. Depending on these factors, policy
recommendations between technologies can differ substan-
tially, and results should be considered in light of the assump-
tions made by the researchers.
Although the EVPI analyses suggest that further research
may be justified to support the future adoption decisions of
cost-effective psychotherapy for cluster B and cluster C PDs,
the partial EVPI analyses for the four groups of parameters
indicate that this may not require an experimental design.
More precise estimates of health state costs, for example,
which account for 45% (cluster B model) and 14% (cluster C
model) of the value of additional information, can be acquired
without an additional clinical trial and can instead be based
on an observational survey. In addition, conducting an obser-
vational study may be more feasible if patients are reluctant to
participate in a trial in which they are randomly assigned to
different psychotherapy treatment groups, as was the experi-
ence of the SCEPTRE study group in the case of cluster C patients
with PDs. Thus, although additional evidence about transition
probabilities is valuable, gathering information on health state
costsmay be preferred, considering the study design required is
less costly andmuchmore feasible in thisparticularpatientpop-
ulation compared to a randomized controlled trial.
A major strength of this study is its use of an integral ap-
proach of state of the art decision-analyticmethods to identify
priority areas for mental health care provision, research, and
implementation. Literature indicates that measures of the bur-
den of disease have been used to allocate research funds to dif-
ferent clinical areas [16–18]. While burden of disease measures
can identifypriority areas for research, theydonot indicate if the
research informingaspecific clinical decision for a specificgroup
of patients is valuable. Value of information and implementa-
tion analysis provide a single framework inwhich themost cost-
effective research as well as implementation strategies can be
identified and is thus consistent with society’s goal of maximiz-
ing health gain given a budget constraint.
Our analysis has a number of limitations. First of all, in our
EVPIM analysis, we optimistically assumed that the current
level of implementation for outpatient psychotherapy for
cluster B PDs is 0.237, and for short-term inpatient psycho-
therapy for cluster C PDs is 0.141. To the extent that the cur-
rent level of implementation based on the SCEPTRE data is
highly influenced by a selection of mental health institutions
that are relatively highly specialized, our results could be con-
sidered conservative. Considering the true capacity for The
Netherlands to provide specialized treatments to patients
with PDsmay bemuch lower, the societal value of implement-
ing these treatment strategies is likely much higher. In addi-
tion, the five-year expected lifetime for psychotherapy was
chosen rather conservatively. One could argue that the life-
time for psychotherapy may be much longer and that there
may be more future patients who can benefit from the addi-
tional evidence, resulting in an even higher societal benefit of
further research.
Secondly, much of the data needed to calculate the total
eligible population for PD treatment (e.g., prevalence rates,
percentage of treatment-seeking patients, percentage of pa-
tients receiving psychotherapy) is not available for The Neth-
erlands; therefore, we relied on data from other settings. Fur-thermore, our calculations were based on the simplifying
assumption that the level of implementation was indepen-
dent of the level of information, which in reality may not be
the case as the amount of information available alters the
implementation effort. The framework could be adapted to in-
corporate this relationship. Finally, asdiscussedearlier, inherent
to the assessment of the EVPI and the EVPIM, information is
rarely perfect. Therefore, the framework could be extended in
order to calculate the expected value of sample information
(EVSI) and the expected value of specific implementation
(EVSIM), indicating the societal value of information from spe-
cific research or of specific implementation strategies.
Despite these limitations, our findings suggest that the so-
cietal value of additional research on treatments for clusters B
and C PDs is substantial, particularly when prioritizing infor-
mation on transition probabilities and health state costs. Fur-
thermore, implementing these cost-effective treatment strat-
egies into clinical practice is likely to improve the efficiency of
health care provision in The Netherlands.
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